DS-8273 / Daiichi Sankyo - LARVOL DELTA

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov) - P1; N=12; Completed; Sponsor: NYU Langone Health; Active, not recruiting ➔ Completed; N=36 ➔ 12; Trial completion date: Mar 2024 ➔ Jan 2021

Clinical • Combination therapy • Enrollment change • Trial completion • Trial completion date • Melanoma • Oncology • Solid Tumor • IL2 • MRI